The BRIUMVI J-Code is now available for dates of service on or after July 1, 2023
J2329, Injection, ublituximab-xiiy, 1 mg

Welcome to BRIUMVI Patient Support!

We’re here to help patients access BRIUMVI

BRIUMVI Patient Support offers a flexible program designed to support the treatment journey in a way that works best for patients

Insurance Support

Patients can receive support in understanding their insurance coverage, eligibility for financial assistance, and educational resources about their infusion.

Copay Assistance

Eligible patients may pay as little as $0 copay per BRIUMVI treatment with an additional benefit to help cover infusion-related costs*

Quick Start

Patients experiencing a coverage delay may be eligible to receive up to their first 2 infusions at no cost.

Enrolling in
BRIUMVI Patient Support

There are 2 simple ways to enroll your patients in BRIUMVI Patient Support, including:

  1. Download the Start Form and fax the completed form to
    1-877-639-2525. Click here to download the Start Form PDF.
  2. eEnroll allows for electronic submission of the Start Form including digital collection of both the patient and prescriber signatures. Click here to complete and submit the form.
Enrolling in
BRIUMVI Copay Assistance Program

Eligible patients can be enrolled by checking the BRIUMVI Copay Assistance Program box on the Start Form. If you do not want to enroll your patient into the full BRIUMVI Patient Support program, but would still like to take advantage of copay assistance, please visit to sign your patients up for the BRIUMVI Copay Assistance Program directly.

* For commercially insured patients only. Other eligibility requirements apply. Click here for full Terms and Conditions.
Delay of 10 business days or more after all required prior authorization documentation has been received by patient’s insurance company. Other terms and conditions may apply.

What is the BRIUMVI Copay Assistance Program?

Treatment Costs

Eligible patients may pay as little as $0 copay per BRIUMVI treatment up to the annual maximum of $20,000

Infusion and Administration Costs

Eligible patients who have out-of-pocket costs may be covered up to $550 for the first infusion and then up to $350 per infusion thereafter

Patients may be eligible if they…
  • Have commercial insurance
  • Are 18 years of age or older

Click here for full BRIUMVI Copay Program Terms and Conditions

Additional assistance for eligible patients

Quick Start

Patients experiencing a delay in insurance coverage of greater than 10 business days may be eligible to receive up to their first 2 infusions (day 1 and day 15) at no cost. Additional terms, conditions, and eligibility criteria apply.

Interim Dose

Patients who are currently on BRIUMVI, who experience a short-term, temporary insurance issue, may be eligible for an interim dose at no cost. Additional terms, conditions, and eligibility criteria apply.

Patient Assistance Program

If eligible, patients may receive BRIUMVI at no charge if the patient is uninsured or underinsured and meets the financial eligibility criteria.  Additional terms, conditions, and eligibility criteria apply.

Patients utilizing these programs may also be eligible for the administration copay benefit to support infusion-related costs

*For commercially insured patients only. Other eligibility requirements apply. Visit for full terms and conditions.
Financial eligibility criteria is based on fixed annual gross household income/household size, as follows: $100k/1, $125k/2, $150k/3, $175k/4 (+$25k for each additional household member).

Get information on how to order BRIUMVI
Download helpful reimbursement resources

Have questions?
Call 1-833-BRIUMVI (1-833-274-8684) to speak with a BRIUMVI Patient Support
Case Manager (Mon-Fri, 8 AM to 8 PM ET)
Sign up for more information and request
a TG Therapeutics representative

Indication and Important Safety Information


BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.


Contraindication: BRIUMVI is contraindicated in patients with:

  • Active HBV infection
  • A history of life-threatening infusion reaction to BRIUMVI


Infusion Reactions:

BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within 24 hours of the first infusion. 0.6% of BRIUMVI-treated patients experienced infusion reactions that were serious, some requiring hospitalization.

Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.

Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was 56% compared to 54% in teriflunomide-treated patients. The rate of serious infections was 5% compared to 3% respectively. There were 3 infection-related deaths in BRIUMVI-treated patients. The most common infections in BRIUMVI-treated patients included upper respiratory tract infection (45%) and urinary tract infection (10%). Delay BRIUMVI administration in patients with an active infection until the infection is resolved.

Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI.

Hepatitis B Virus (HBV) Reactivation: HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HBsAg and anti-HB tests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment.

Progressive Multifocal Leukoencephalopathy (PML): Although no cases of PML have occurred in BRIUMVI-treated MS patients, JCV infection resulting in PML has been observed in patients treated with other anti-CD20 antibodies and other MS therapies.

If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.

MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis.

If PML is confirmed, treatment with BRIUMVI should be discontinued.

Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines at least 4 weeks and, whenever possible at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion.

Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy: In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.

Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. A pregnancy test is recommended in females of reproductive potential prior to each infusion. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose.

Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in 0.6% of BRIUMVI-treated patients compared to none of the patients treated with teriflunomide in RMS clinical trials. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. Consider discontinuing BRIUMVI therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.

Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least 10%) were infusion reactions and upper respiratory tract infections.